See more : OXIDE Corporation (6521.T) Income Statement Analysis – Financial Results
Complete financial analysis of Myomo, Inc. (MYO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myomo, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Bank of Chongqing Co., Ltd. (1963.HK) Income Statement Analysis – Financial Results
- GMR Airports Infrastructure Limited (GMRINFRA.BO) Income Statement Analysis – Financial Results
- Waldencast plc (WALDW) Income Statement Analysis – Financial Results
- Enova International, Inc. (ENVA) Income Statement Analysis – Financial Results
- Nippon Densetsu Kogyo Co., Ltd. (1950.T) Income Statement Analysis – Financial Results
Myomo, Inc. (MYO)
About Myomo, Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.24M | 15.56M | 13.86M | 7.58M | 3.84M | 2.44M | 1.56M | 1.10M | 689.67K | 913.25K |
| Cost of Revenue | 6.06M | 5.30M | 3.54M | 2.60M | 917.62K | 728.28K | 505.28K | 282.16K | 244.41K | 211.58K |
| Gross Profit | 13.18M | 10.25M | 10.31M | 4.98M | 2.92M | 1.72M | 1.05M | 821.11K | 445.26K | 701.67K |
| Gross Profit Ratio | 68.51% | 65.91% | 74.42% | 65.71% | 76.09% | 70.20% | 67.59% | 74.42% | 64.56% | 76.83% |
| Research & Development | 2.64M | 2.48M | 2.56M | 1.67M | 2.16M | 1.84M | 1.75M | 1.12M | 869.13K | 675.21K |
| General & Administrative | 16.02M | 14.37M | 14.44M | 12.98M | 11.25M | 10.41M | 5.85M | 2.93M | 3.10M | 2.85M |
| Selling & Marketing | 3.22M | 4.07M | 3.59M | 841.30K | 301.70K | 136.30K | 31.00K | 41.60K | 119.70K | 14.30K |
| SG&A | 18.78M | 18.44M | 18.02M | 13.82M | 11.55M | 10.41M | 5.85M | 2.98M | 3.22M | 2.86M |
| Other Expenses | 0.00 | -1.10K | -16.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.41M | 20.93M | 20.58M | 15.49M | 13.72M | 12.24M | 7.60M | 4.10M | 3.98M | 3.44M |
| Cost & Expenses | 27.47M | 26.23M | 24.12M | 18.09M | 14.63M | 12.97M | 8.11M | 4.38M | 4.22M | 3.65M |
| Interest Income | 410.27K | 88.73K | 1.61K | 474.71K | 112.49K | 0.00 | 0.00 | 0.00 | 196.06K | 178.86K |
| Interest Expense | 0.00 | 88.73K | 15.34K | 474.71K | 113.63K | 358.92K | 358.92K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 517.68K | 542.63K | 335.96K | 108.67K | 95.12K | 69.68K | 11.42K | 7.73K | 5.31K | 6.16K |
| EBITDA | -7.71M | -10.13M | -9.93M | -11.24M | -10.70M | -10.46M | -6.54M | -3.27M | -3.53M | -2.74M |
| EBITDA Ratio | -40.09% | -65.12% | -71.68% | -137.06% | -283.88% | -429.40% | -86.36% | -296.14% | -511.58% | -299.50% |
| Operating Income | -8.23M | -10.67M | -10.27M | -10.50M | -10.80M | -10.53M | -6.55M | -3.28M | -3.53M | -2.74M |
| Operating Income Ratio | -42.78% | -68.61% | -74.10% | -138.50% | -281.29% | -430.77% | -420.06% | -296.84% | -512.35% | -300.17% |
| Total Other Income/Expenses | 239.99K | 21.12K | -15.34K | -1.06M | 81.99K | 211.68K | -5.55M | -342.02K | -196.06K | -178.86K |
| Income Before Tax | -7.99M | -10.65M | -10.28M | -11.56M | -10.71M | -10.32M | -12.10M | -3.62M | -3.73M | -2.92M |
| Income Before Tax Ratio | -41.53% | -68.47% | -74.21% | -152.49% | -279.15% | -422.11% | -776.04% | -327.84% | -540.77% | -319.76% |
| Income Tax Expense | 156.00K | 69.94K | 88.93K | 474.71K | -81.99K | -247.95K | 5.57M | 342.02K | 752.61K | 607.62K |
| Net Income | -8.15M | -10.72M | -10.37M | -12.04M | -10.63M | -10.32M | -12.10M | -3.62M | -4.48M | -3.53M |
| Net Income Ratio | -42.34% | -68.92% | -74.86% | -158.75% | -277.01% | -422.11% | -776.04% | -327.84% | -649.90% | -386.29% |
| EPS | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.18 | -84.05 | -0.56 | -134.56 | -106.03 |
| EPS Diluted | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.15 | -84.05 | -0.56 | -134.56 | -106.03 |
| Weighted Avg Shares Out | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 409.75K | 143.93K | 6.41M | 33.31K | 33.27K |
| Weighted Avg Shares Out (Dil) | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 410.15K | 143.93K | 6.41M | 33.31K | 33.27K |
Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of...
Myomo, Inc. Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock...
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago.
CMS Decision And O&P Network Build Out Make Myomo A Buy
Myomo's business model is now sustainable due to CMS reclassifying MyoPro, leading to lump sum payments and consistent insurance coverage. Medicare Part B coverage has significantly improved Myomo's operating margin and accelerated its product sales growth. The development of an...
Myomo to Report Third Quarter Financial Results on November 6, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter...
Myomo to Participate in the 2024 Maxim Healthcare Virtual Summit
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer, and David...
Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the official launch of the Myomo Academy, a comprehensive learning...
Myomo to Participate in Two Investor Conferences in September
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be participating in two investor conferences during...
Myomo, Inc. (MYO) Q2 2024 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Chase Knickerbocker...
Source: https://incomestatements.info
Category: Stock Reports